---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009315"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:01:27.979020+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# David Johnson appointed to Caribou board; brings 30 years biopharma commercial experience

## Summary
- Board expanded from 7 to 8 directors; Johnson appointed effective May 11, 2022.
- Annual cash compensation of $40,000; initial option for 44,000 shares vesting over 3 years.
- Johnson was CCO at Global Blood Therapeutics and spent 15 years at Gilead in commercial roles.
- No immediate committee assignments; standard indemnification agreement entered.

## SEC filing metadata
- accession: 0000950170-22-009315
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/0000950170-22-009315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/crbu-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009315
- JSON: https://secwatch.observer/filing/0000950170-22-009315.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009315.txt

## Key facts
- Executive change
  David L. Johnson was appointed as Class II director at Caribou Biosciences, Inc..
  - Action: appointed
  - Role: Class II director
  source text: increased the size of the Board from seven to eight directors and unanimously agreed to extend an offer to David L. Johnson, M.B.A., to serve as a Class II director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000095017022009315/0000950170-22-009315-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.